HCP (NYSE:HCP) is set to post its quarterly earnings results after the market closes on Wednesday, July 31st. Analysts expect HCP to post earnings of $0.43 per share for the quarter. HCP has set its FY19 guidance at $1.70-1.76 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.
HCP (NYSE:HCP) last posted its quarterly earnings results on Wednesday, May 1st. The real estate investment trust reported $0.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.01. HCP had a net margin of 59.96% and a return on equity of 18.05%. The company had revenue of $436.15 million during the quarter, compared to the consensus estimate of $442.20 million. During the same period last year, the firm earned $0.48 EPS. The company’s revenue for the quarter was down 9.0% on a year-over-year basis. On average, analysts expect HCP to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
HCP stock opened at $32.08 on Tuesday. The firm’s 50 day moving average is $32.26. HCP has a 12-month low of $24.47 and a 12-month high of $33.58. The company has a debt-to-equity ratio of 0.90, a quick ratio of 0.80 and a current ratio of 0.80. The firm has a market cap of $15.33 billion, a P/E ratio of 17.63, a price-to-earnings-growth ratio of 6.97 and a beta of 0.31.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, August 20th. Stockholders of record on Monday, August 5th will be given a dividend of $0.37 per share. The ex-dividend date of this dividend is Friday, August 2nd. This represents a $1.48 dividend on an annualized basis and a dividend yield of 4.61%. HCP’s payout ratio is 81.32%.
In related news, Director Christine Garvey sold 3,405 shares of HCP stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $29.80, for a total transaction of $101,469.00. Following the completion of the transaction, the director now directly owns 5,348 shares in the company, valued at approximately $159,370.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.
Several research analysts recently issued reports on HCP shares. KeyCorp downgraded GTT Communications from an “overweight” rating to a “sector weight” rating in a research report on Monday, July 1st. TheStreet upgraded Rent-A-Center from a “c” rating to a “b-” rating in a research report on Tuesday, May 7th. Finally, Raymond James started coverage on Adverum Biotechnologies in a research report on Thursday, June 13th. They set a “market perform” rating for the company. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $30.70.
HCP Company Profile
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Further Reading: What does a market perform rating mean?
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.